Neuroendocrine Carcinoma

This is a group of cancers that start in cells that produce hormones. They can occur in many parts of the body, including the lungs, thyroid, and pancreas. They often grow and spread quickly.

Condition

What people with Neuroendocrine Carcinoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Etoposide for Neuroendocrine Carcinoma?

NameHow it went

About Neuroendocrine Carcinoma

What It Is

Neuroendocrine carcinoma (NEC) is a fast-growing cancer that starts in neuroendocrine cells, which share features of nerve cells and hormone-making cells and are found in organs such as the lungs, digestive tract and pancreas. Under the microscope, the cancer cells look very different from normal cells and divide rapidly. Pathologists describe two main types, small cell and large cell, which behave and are treated in similar ways. The name is easily confused with neuroendocrine tumors (NETs, once called carcinoids). Those are usually slow-growing, are treated differently and only rarely turn into a carcinoma. Neuroendocrine carcinoma is the aggressive end of the same family: it tends to spread early, and it calls for prompt treatment. About nine in ten neuroendocrine carcinomas start in the lung, mostly as small cell lung cancer. The rest, called extrapulmonary NECs, are rare. About a third of these begin in the digestive tract, such as the esophagus, stomach, pancreas, colon or rectum, and in about a quarter the starting point is never found. Others arise in the bladder, prostate, cervix, head and neck, or skin, where it is called Merkel cell carcinoma. This page focuses mainly on NECs outside the lung. Symptoms depend on where the cancer starts and where it has spread. A cancer in the digestive tract may first cause vague abdominal pain or a change in bowel habits. Because most of these cancers have already spread by the time they are found, symptoms often come from secondary tumors, most commonly in the liver.

Causes & Risk Factors

For most people with a neuroendocrine carcinoma outside the lung, no clear cause is found. Like other cancers, it develops when cells acquire genetic changes that let them grow out of control, and those changes are usually not inherited. Smoking is the main exception. It is the most important risk factor for lung cancer, including the small cell type that makes up most neuroendocrine carcinomas. The link to smoking is weaker for NECs that start elsewhere. Merkel cell carcinoma, the skin form, is linked to a common virus (Merkel cell polyomavirus) and to long-term sun exposure. A neuroendocrine carcinoma can also grow out of another cancer. Some prostate cancers treated with hormone-blocking medicines, and some lung cancers treated with targeted pills, change into a neuroendocrine form that no longer responds to those drugs. This is different from a slow-growing neuroendocrine tumor turning into a carcinoma, which is rare.

How It's Diagnosed

The diagnosis is made from a biopsy, a tissue sample examined by a pathologist. Special stains show whether the cells make neuroendocrine proteins such as synaptophysin and chromogranin A, and the look of the cells shows whether the cancer is the small cell or large cell type. A key measurement is the Ki-67 index, the share of cancer cells that are actively dividing. In neuroendocrine carcinoma it is above 20%, and often above half, while slow-growing neuroendocrine tumors are usually far lower. A high Ki-67 alone does not settle the question, because some well-differentiated tumors (grade 3 NETs) also exceed 20%. The pathologist also judges how abnormal the cells look, and since that distinction changes treatment, review by a pathologist experienced with these cancers is worthwhile. Scans then show how far the cancer has spread and, when the starting point is unclear, search for it. Alongside computed tomography (CT) or magnetic resonance imaging (MRI), the scan generally used for neuroendocrine carcinoma is FDG PET/CT: a positron emission tomography (PET) scan after an injection of fluorodeoxyglucose (FDG), a mildly radioactive form of sugar that fast-growing cancers take up readily. Before any surgery, this kind of scan is used to make sure there is no hidden spread.

Treatment Options

Because these cancers are rare and behave differently from more common cancers of the same organs, treatment is best planned by a team that includes surgeons, cancer specialists, radiologists and pathologists, ideally at a center experienced with neuroendocrine cancers. When the cancer has not spread, surgery to remove it can be worthwhile, but only after thorough imaging has ruled out hidden spread. The cancer often returns after surgery, so chemotherapy is commonly added, although no randomized trials have tested this. For some sites, such as the esophagus and anus, chemotherapy combined with radiation is often used. For cancer that has spread, which is the more common situation, chemotherapy is the main treatment. The usual first choice combines a platinum drug (carboplatin or cisplatin) with etoposide, the same approach used for small cell lung cancer. Carboplatin is often easier to tolerate and does not need the hours of intravenous fluids that cisplatin requires. More than half of people see their cancer shrink, but the effect usually lasts months rather than years. These drugs lower white blood cell counts, which makes serious infections a real risk during treatment. When the cancer grows again, options are more limited. Irinotecan combined with a fluorouracil-type drug has the best evidence, but it helps fewer people and for a shorter time. Immunotherapy, which helps the immune system attack cancer, has played a small role in NECs outside the lung unless tests show specific features of the tumor, though it is added to chemotherapy in small cell lung cancer and is a main treatment for Merkel cell carcinoma. Molecular testing of the tumor can sometimes reveal a change that a targeted drug can act on, and clinical trials are an important option at any stage.

What to Expect

Neuroendocrine carcinoma is a serious cancer that usually moves faster than most other cancers of the same organs. Outside the lung, most people are diagnosed after it has spread. In studies of digestive NEC that had spread, the median survival was about 11 to 12 months, meaning half of people lived for less time and half for longer. These figures describe groups, not individuals: the outlook is better when the cancer is found before it spreads and can be removed, and individual courses vary widely. Chemotherapy is given in cycles over several months, with scans in between to check whether it is working. Because the cancer often returns, scans continue after treatment ends, and plans can change quickly if it grows. Care also involves managing symptoms, nutrition and treatment side effects. Given how quickly the situation can change, many people find it useful to talk early with their team about goals of care: what matters most, how much treatment they want, and how to balance time spent in treatment with the rest of life. Social workers, palliative care specialists and support groups for neuroendocrine cancers can help with symptoms, practical needs and the emotional weight of the diagnosis.

When to Seek Help

See a doctor about symptoms that persist without a clear explanation, such as ongoing abdominal pain, a lasting change in bowel habits or a new lump. If you are being treated for prostate or lung cancer and it grows despite treatment that had been working, ask whether a new biopsy is needed. During chemotherapy, call your care team right away for a temperature of 100.4°F (38°C) or higher, since a low white blood cell count can let an infection become serious quickly. Contact the team promptly about new or rapidly worsening symptoms between visits, because this cancer can change quickly.

Questions to Ask Your Doctor

  1. 1.Is this a neuroendocrine carcinoma or a well-differentiated neuroendocrine tumor, and has a pathologist experienced with these cancers reviewed the biopsy?
  2. 2.Where did the cancer start, and how far has it spread on PET or other scans?
  3. 3.Is surgery or radiation an option for me, or is chemotherapy the main treatment?
  4. 4.What is the goal of treatment, and what benefit and side effects can I realistically expect?
  5. 5.Should my tumor have molecular testing, and are there clinical trials I could join?

Last reviewed • Oct 2026

Educational content, not medical advice.